The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was $230.50 for the day, down -0.19% from the previous closing price of $230.93. In other words, the price has decreased by -$0.19 from its previous closing price. On the day, 1.01 million shares were traded. ALNY stock price reached its highest trading level at $234.5 during the session, while it also had its lowest trading level at $225.8448.
Ratios:
Our analysis of ALNY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.71 and its Current Ratio is at 2.78. In the meantime, Its Debt-to-Equity ratio is 40.89 whereas as Long-Term Debt/Eq ratio is at 38.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on March 31, 2025, initiated with a Buy rating and assigned the stock a target price of $353.
On March 24, 2025, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $280 to $328.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 24 ’25 when Garg Pushkal sold 5,445 shares for $300.00 per share. The transaction valued at 1,633,500 led to the insider holds 20,221 shares of the business.
Garg Pushkal sold 4,321 shares of ALNY for $1,231,485 on Mar 21 ’25. The CMO & EVP Dev & Med Affairs now owns 20,221 shares after completing the transaction at $285.00 per share. On Mar 24 ’25, another insider, PYOTT DAVID E I, who serves as the Director of the company, sold 7,440 shares for $299.00 each. As a result, the insider received 2,224,560 and left with 136 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 29832923136 and an Enterprise Value of 29888788480. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.34 while its Price-to-Book (P/B) ratio in mrq is 444.23. Its current Enterprise Value per Revenue stands at 13.294 whereas that against EBITDA is -248.628.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.22, which has changed by 0.587903 over the last 52 weeks, in comparison to a change of 0.05279863 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $304.39, while it has fallen to a 52-week low of $141.98. The 50-Day Moving Average of the stock is -8.79%, while the 200-Day Moving Average is calculated to be -11.01%.
Shares Statistics:
ALNY traded an average of 898.38K shares per day over the past three months and 1380100 shares per day over the past ten days. A total of 129.29M shares are outstanding, with a floating share count of 124.35M. Insiders hold about 4.40% of the company’s shares, while institutions hold 95.68% stake in the company. Shares short for ALNY as of 1743379200 were 2989679 with a Short Ratio of 3.33, compared to 1740700800 on 2493180. Therefore, it implies a Short% of Shares Outstanding of 2989679 and a Short% of Float of 3.06.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
